Streamline Bio offers an autonomous, cost-effective, AI-driven precision robotic platform for end-to-end cell and gene therapy (CGT) production. Our plug-and-play technology is easy to use and seamlessly integrates into your current manufacturing. Advanced automation. No rebuild required.
No custom enclosures. No facility redesign. Streamline Bio seamlessly integrates with your existing infrastructure—plug-and-play with your devices, protocols, and compliance systems.
Automation, without the rebuild.
Autonomous, AI-driven systems engineered for the complexities of CGT production—delivering repeatable precision, reduced manual touchpoints, and seamless, end-to-end automation.
Our modular, plug-and-play architecture scales alongside your pipeline—adapting to new therapies and workflows without the need to overhaul your existing infrastructure.
Our modular plug-and-play platform is designed to be process agnostic, device-agnostic, and footprint agnostic; enabling it to seamlessly integrate into your existing infrastructure with minimal costs and no workflow restrictions
We believe in growing together. In these early stages, we collaborate closely with CGT developers—offering flexible engagement models and deep technical support to co-create scalable solutions. Our goal is to be more than a vendor—we’re your long-term partner in bringing transformative therapies to patients for your manufacturing process.
By mimicking how operators direct existing devices (via touch), we can largely avoid cumbersome and costly 21CFR11 compliance regulations.
Precision robotics decreases run-to-run variation and training burdens; enabling standardization and high-fidelity manufacturing.
From IND to clinical trial to commercial scale —Streamline Bio evolves with your facility, SOPs, and devices — no rebuild required.
Engineered for autologous and allogeneic workflows, handling soft materials, delicate tubing, and patient-specific variability with minimal operator intervention.